Adjunctive laser‐stimulated stem‐cells therapy to primary reperfusion in acute myocardial infarction in humans: Safety and feasibility study

Elbaz‐Greener, Gabby; Sud, Maneesh; Tzuman, Oran; Leitman, Marina; Vered, Zvi; Ben–Dov, Nissan; Oron, Uri; Blatt, Alex

doi:10.1111/joic.12539

Cited by 13 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9][10][11][12][13][14][15][16] In a series of studies using animal models and human clinical trials, several investigators have demonstrated the utility of PBM therapy in improving cardiovascular functional recovery after cardiac infarcts. 22,[36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55] The benefits of PBM treatments in these acute MI models demonstrated reduced infarct size (33% to 77%), positive modulation of cardiovascular functions (LV mass and functions), and modulation of inflammatory cytokines (IL1β, IL-6, VEGF) and oxidative stress (SOD, NO, GPX) factors affecting overall improvement in cardiac functions. The acute infarct model represents an immediate, aggravated disruption of cardiac functions in contrast to the subtle, chronic damage in AC8 mice.…”

Section: Discussionmentioning

confidence: 93%

“…PBM treatments have been noted to promote several cardioprotective effects such as improved cell viability and restoration of functions following ischemia‐perfusion injury, functional cardiovascular recovery following myocardial infarction, promotes angiogenesis and prevented the aortic aneurysm formation and progression 9–16 . In a series of studies using animal models and human clinical trials, several investigators have demonstrated the utility of PBM therapy in improving cardiovascular functional recovery after cardiac infarcts 22,36–55 . The benefits of PBM treatments in these acute MI models demonstrated reduced infarct size (33% to 77%), positive modulation of cardiovascular functions (LV mass and functions), and modulation of inflammatory cytokines (IL1β, IL‐6, VEGF) and oxidative stress (SOD, NO, GPX) factors affecting overall improvement in cardiac functions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Photobiomodulation therapy mitigates cardiovascular aging and improves survival

Syed¹,

Ahmet²,

Chakir³

et al. 2023

Lasers Surg Med

View full text Add to dashboard Cite

Background: Photobiomodulation (PBM) therapy, a form of low-dose light therapy, has been noted to be effective in several age-associated chronic diseases such as hypertension and atherosclerosis. Here, we examined the effects of PBM therapy on age-associated cardiovascular changes in a mouse model of accelerated cardiac aging. Methods: Fourteen months old Adenylyl cyclase type VIII (AC8) overexpressing transgenic mice (n = 8) and their wild-type (WT) littermates (n = 8) were treated with daily exposure to Near-Infrared Light (850 nm) at 25 mW/cm 2 for 2 min each weekday for a total dose of 1 Einstein (4.5 p.J/cm 2 or fluence 3 J/cm 2 ) and compared to untreated controls over an 8-month period. PBM therapy was administered for 3.5 months (Early Treatment period), paused, due to Covid-19 restrictions for the following 3 months, and restarted again for 1.5 months. Serial echocardiography and gait analyses were performed at monthly intervals, and serum TGF-β1 levels were assessed following sacrifice. Results: During the Early Treatment period PBM treatments: reduced the ageassociated increases in left ventricular (LV) mass in both genotypes (p = 0.0003), reduced the LV end-diastolic volume (EDV) in AC8 (p = 0.04); and reduced the left atrial dimension in both genotypes (p = 0.02). PBM treatments substantially increased the LV ejection fraction (p = 0.03), reduced the aortic wall stiffness (p = 0.001), and improved gait symmetry, an index of neuro-muscular coordination (p = 0.005). The effects of PBM treatments, measured following the pause, persisted. Total TGF-β1 levels were significantly increased in circulation (serum) in AC8 following PBM treatments (p = 0.01). We observed a striking increase in cumulative survival in PBM-treated AC8 mice (100%; p = 0.01) compared to untreated AC8 mice (43%). Conclusion: PBM treatment mitigated age-associated cardiovascular remodeling and reduced cardiac function, improved neuromuscular coordination, and increased longevity in an experimental animal model. These responses correlate with increased TGF-β1 in circulation. Future mechanistic and dose optimization studies are necessary to assess these anti-aging effects of PBM, and validation in future controlled human studies is required for effective clinical translation.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Photobiomodulation therapy mitigates cardiovascular aging and improves survival

Syed¹,

Ahmet²,

Chakir³

et al. 2023

Lasers Surg Med

View full text Add to dashboard Cite

show abstract

“…81 In addition, a laser therapy applied to the tibia bone before and 24 and 72 hours after PCI reduced the troponin-T levels, with few adverse effects, but no differences were found in LVEF. 82…”

Section: Stem Cellsmentioning

confidence: 99%

Reperfusion Strategies in Acute Myocardial Infarction: State of the Art

Rangel¹

2021

International Journal of Cardiovascular Sciences

View full text Add to dashboard Cite

ST elevation myocardial infarction (STEMI) is a highly prevalent condition worldwide. Reperfusion therapy is strongly associated with the prognosis of STEMI and must be performed with a high standard of quality and without delay. A systematic review of different reperfusion strategies for STEMI was conducted, including randomized controlled trials that included major cardiovascular events (MACE), and systematic reviews in the last 5 years through the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) methodology. The research was done in the PubMed and Cochrane Central Register of Controlled Trials databases, in addition to a few manual searches. After the exclusion criteria were applied, 90 articles were selected for this review. Despite the reestablishment of IRA patency in PCI for STEMI, microvascular lesions occur in a significant proportion of these patients, which can compromise ventricular function and clinical course. Several therapeutic strategies -intracoronary administration of nicorandil, nitrates, melatonin, antioxidant drugs (quercetin, glutathione), antiinflammatory substances (tocilizumab [an inhibitor of interleukin 6], inclacumab, P-selectin inhibitor), immunosuppressants (cyclosporine), erythropoietin and ischemic pre-and post-conditioning and stem cell therapy -have been tested to reduce reperfusion injury, ventricular remodeling and serious cardiovascular events, with heterogeneous results: These therapies need confirmation in larger studies to be implemented in clinical practice PrevalenceThe worldwide prevalence of ischemic heart disease is approximately 111 million cases, with 7.3 million cases of fatal acute myocardial infarction (AMI) in 2015. The inadequate treatment of patients with AMI is associated with significant increases in morbidity and mortality. 1 ObjectivesThe objective of this systematic review is to evaluate the evidence of different reperfusion therapies in STsegment elevation AMI (STEMI), selecting mainly randomized controlled trials and systematic reviews that address major cardiovascular clinical outcomes. MethodsThe review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). We searched the PubMed database for the terms "acute myocardial infarction" and "reperfusion therapy", which yielded 9,885 results. After applying the following search filters -type of abstract: "text and full text"; type of article: "metaanalysis, review, systematic review and randomized clinical trial", and date of publication: "last 5 years", and language: "English" -127 articles were obtained. In addition, research was conducted at the Cochrane Central Register of Controlled Trials using the terms "acute myocardial infarction" and "reperfusion therapy", in English, between 2018 and 2020, which revealed 64 clinical trials, already excluding duplicates. Of the 191

show abstract

“…A follow-up clinical study was designed to determine the long-term safety and possible feasibility of PBM application to the BM in patients with acute myocardial infarction (AMI). 20 The study comprised patients suffering from acute ST segment elevation myocardial infarction (STEMI) and candidates for primary percutaneous coronary intervention (PPCI). In the active group (rPBMT, LT group), PBMT was applied to the tibia bone noninvasively before PPCI, 24 and 72 h post-PPCI.…”

mentioning

confidence: 99%

Adjunctive laser‐stimulated stem‐cells therapy to primary reperfusion in acute myocardial infarction in humans: Safety and feasibility study

Abstract: LLLT is a safe and feasible adjunctive cell-based therapy to PPCI that may benefit ischemic myocardium.

Cited by 13 publications

References 23 publications

Photobiomodulation therapy mitigates cardiovascular aging and improves survival

Photobiomodulation therapy mitigates cardiovascular aging and improves survival

Reperfusion Strategies in Acute Myocardial Infarction: State of the Art

Photobiomodulation Therapy of Cells in the Bone Marrow: A Novel Therapeutic Approach in Cell Therapy and Regenerative Medicine

Contact Info

Product

Resources

About